These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 30489256)
1. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Fanning SW; Jeselsohn R; Dharmarajan V; Mayne CG; Karimi M; Buchwalter G; Houtman R; Toy W; Fowler CE; Han R; Lainé M; Carlson KE; Martin TA; Nowak J; Nwachukwu JC; Hosfield DJ; Chandarlapaty S; Tajkhorshid E; Nettles KW; Griffin PR; Shen Y; Katzenellenbogen JA; Brown M; Greene GL Elife; 2018 Nov; 7():. PubMed ID: 30489256 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817 [TBL] [Abstract][Full Text] [Related]
3. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285 [TBL] [Abstract][Full Text] [Related]
4. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW Elife; 2022 May; 11():. PubMed ID: 35575456 [TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Fanning SW; Mayne CG; Dharmarajan V; Carlson KE; Martin TA; Novick SJ; Toy W; Green B; Panchamukhi S; Katzenellenbogen BS; Tajkhorshid E; Griffin PR; Shen Y; Chandarlapaty S; Katzenellenbogen JA; Greene GL Elife; 2016 Feb; 5():. PubMed ID: 26836308 [TBL] [Abstract][Full Text] [Related]
6. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1. Lewis-Wambi JS; Kim H; Curpan R; Grigg R; Sarker MA; Jordan VC Mol Pharmacol; 2011 Oct; 80(4):610-20. PubMed ID: 21737572 [TBL] [Abstract][Full Text] [Related]
7. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials. Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985 [TBL] [Abstract][Full Text] [Related]
8. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer. Lu Y; Liu W J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369 [TBL] [Abstract][Full Text] [Related]
9. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Brett JO; Spring LM; Bardia A; Wander SA Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831 [TBL] [Abstract][Full Text] [Related]
10. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models. Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569 [TBL] [Abstract][Full Text] [Related]
11. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast. Pickar JH; Komm BS Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836 [TBL] [Abstract][Full Text] [Related]
12. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer. Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153 [TBL] [Abstract][Full Text] [Related]
13. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794 [TBL] [Abstract][Full Text] [Related]
14. Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Lainé M; Greene ME; Kurleto JD; Bozek G; Leng T; Huggins RJ; Komm BS; Greene GL Breast Cancer Res; 2024 Jun; 26(1):95. PubMed ID: 38849889 [TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor α L543A,L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity. Arao Y; Hamilton KJ; Coons LA; Korach KS J Biol Chem; 2013 Jul; 288(29):21105-21116. PubMed ID: 23733188 [TBL] [Abstract][Full Text] [Related]
16. Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition. Udden SN; Wang Q; Kumar S; Malladi VS; Wu SY; Wei S; Posner BA; Geboers S; Williams NS; Liu Y; Sharma JK; Mani RS; Malladi S; Parra K; Hofstad M; Raj GV; Larios JM; Jagsi R; Wicha MS; Park BH; Gupta GP; Chinnaiyan AM; Chiang CM; Alluri PG JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35881485 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity. Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092 [TBL] [Abstract][Full Text] [Related]
18. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462 [TBL] [Abstract][Full Text] [Related]
19. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms. Long X; Fan M; Bigsby RM; Nephew KP Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020 [TBL] [Abstract][Full Text] [Related]
20. Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs. Nichols M; Cheng P; Liu Y; Kanterewicz B; Hershberger PA; McCarty KS Breast Cancer Res Treat; 2010 Apr; 120(3):761-8. PubMed ID: 19526339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]